JP2017515843A5 - - Google Patents

Download PDF

Info

Publication number
JP2017515843A5
JP2017515843A5 JP2016567491A JP2016567491A JP2017515843A5 JP 2017515843 A5 JP2017515843 A5 JP 2017515843A5 JP 2016567491 A JP2016567491 A JP 2016567491A JP 2016567491 A JP2016567491 A JP 2016567491A JP 2017515843 A5 JP2017515843 A5 JP 2017515843A5
Authority
JP
Japan
Prior art keywords
composition
administered
dose
rate
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2016567491A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017515843A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/030870 external-priority patent/WO2015175827A1/en
Publication of JP2017515843A publication Critical patent/JP2017515843A/ja
Publication of JP2017515843A5 publication Critical patent/JP2017515843A5/ja
Withdrawn legal-status Critical Current

Links

JP2016567491A 2014-05-14 2015-05-14 抗ｅｇｆｒ治療薬の投与量および投与 Withdrawn JP2017515843A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201461996819P 2014-05-14 2014-05-14
US61/996,819 2014-05-14
US201462005401P 2014-05-30 2014-05-30
US62/005,401 2014-05-30
PCT/US2015/030870 WO2015175827A1 (en) 2014-05-14 2015-05-14 Dosage and administration anti-egfr therapeutics

Publications (2)

Publication Number Publication Date
JP2017515843A JP2017515843A (ja) 2017-06-15
JP2017515843A5 true JP2017515843A5 (enExample) 2018-06-21

Family

ID=53366255

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016567491A Withdrawn JP2017515843A (ja) 2014-05-14 2015-05-14 抗ｅｇｆｒ治療薬の投与量および投与

Country Status (8)

Country Link
US (4) US9657108B2 (enExample)
EP (1) EP3074422A1 (enExample)
JP (1) JP2017515843A (enExample)
KR (1) KR20170002600A (enExample)
AU (1) AU2015259019A1 (enExample)
HK (1) HK1223630A1 (enExample)
MA (1) MA39599A (enExample)
WO (1) WO2015175827A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
WO2017172678A1 (en) * 2016-03-30 2017-10-05 Merrimack Pharmaceuticals, Inc. Methods for treating cancer using combination therapies comprising an oligoclonal anti-egfr antibody preparation and lipsomal irinotecan
KR20180123265A (ko) * 2017-05-08 2018-11-16 에스케이하이닉스 주식회사 메모리 시스템 및 메모리 시스템의 동작 방법

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
CA2436326C (en) 2001-01-09 2012-08-14 Merck Patent Gesellschaft Mit Beschraenkter Haftung Combination therapy using receptor tyrosine kinase inhibitors and angiogenesis inhibitors
WO2004000102A2 (en) 2002-06-19 2003-12-31 Abgenix, Inc. Method for predicting response to epidermal growth factor receptor-directed therapy
JP2006505546A (ja) 2002-10-10 2006-02-16 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 二重特異性抗ＥｒｂＢ抗体および腫瘍治療でのその使用
US8008003B2 (en) 2002-11-15 2011-08-30 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20050003403A1 (en) 2003-04-22 2005-01-06 Rossi Edmund A. Polyvalent protein complex
PT1687338E (pt) 2003-11-07 2011-01-20 Ablynx Nv Anticorpos de domínio único vhh de camelídeos direccionados para o receptor do factor de crescimento epidérmico e suas utilizações
KR101462825B1 (ko) 2004-05-03 2014-11-21 헤르메스 바이오사이언스, 인코포레이티드 약물 전달에 유용한 리포좀
US7498142B2 (en) 2006-01-31 2009-03-03 Yeda Research And Development Co., Ltd. Methods of identifying combinations of antibodies with an improved anti-tumor activity and compositions and methods using the antibodies
ES2809168T3 (es) 2006-11-15 2021-03-03 Biofire Diagnostics Llc Análisis biológico autónomo de alta densidad
TW200846362A (en) 2007-02-09 2008-12-01 Symphogen As A polyclonal antibody product
BRPI0808551B1 (pt) 2007-03-01 2022-04-05 Symphogen A/S Composições de anticorpo para o receptor do fator de crescimento antiepidérmico recombinante, molécula de ligação bi-específica e composição farmacêutica que os compreende
WO2009030239A1 (en) 2007-09-06 2009-03-12 Genmab A/S Novel methods and antibodies for treating cancer
WO2009036379A2 (en) 2007-09-14 2009-03-19 Adimab, Inc. Rationally designed, synthetic antibody libraries and uses therefor
US8159931B2 (en) 2007-12-11 2012-04-17 Broadcom Corporation Orthogonal pilot code construction
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
NZ589143A (en) 2008-05-14 2012-02-24 Genomic Health Inc Colorectal cancer response prediction based on AREG EREG DUSP6 and SLC26A3 expression levels
KR20110044905A (ko) 2008-08-15 2011-05-02 메리맥 파마슈티컬즈, 인크. 치료제에 대한 세포의 반응을 예측하는 방법 및 시스템
WO2011132182A1 (en) 2010-04-18 2011-10-27 Yeda Research And Development Co. Ltd. MOLECULES AND METHODS OF USING SAME FOR TREATING ErbB/ErbB LIGANDS ASSOCIATED DISEASES
WO2011140254A1 (en) 2010-05-04 2011-11-10 Adimab, Llc Antibodies against epidermal growth factor receptor (egfr) and uses thereof
WO2011140151A1 (en) 2010-05-04 2011-11-10 Dyax Corp. Antibodies against epidermal growth factor receptor (egfr)
EP2815765A1 (en) 2011-03-15 2014-12-24 Merrimack Pharmaceuticals, Inc. Overcoming resistance to ERBB pathway inhibitors
US8691231B2 (en) 2011-06-03 2014-04-08 Merrimack Pharmaceuticals, Inc. Methods of treatment of tumors expressing predominantly high affinity EGFR ligands or tumors expressing predominantly low affinity EGFR ligands with monoclonal and oligoclonal anti-EGFR antibodies
EP2554551A1 (en) 2011-08-03 2013-02-06 Fundacio Institut mar d'Investigacions Médiques (IMIM) Mutations in the epidermal growth factor receptor gene
WO2013138371A1 (en) 2012-03-12 2013-09-19 Merrimack Pharmaceuticals, Inc. Methods for treating pancreatic cancer using combination therapies comprising an anti-erbb3 antibody
AU2013202947B2 (en) 2012-06-13 2016-06-02 Ipsen Biopharm Ltd. Methods for treating pancreatic cancer using combination therapies comprising liposomal irinotecan
MA39599A (fr) 2014-05-14 2016-10-05 Merrimack Pharmaceuticals Inc Dosage et administration d'agents thérapeutiques anti-egfr
EP3286219A1 (en) 2015-04-24 2018-02-28 Merrimack Pharmaceuticals, Inc. Methods of treating patients having mutations in the extracellular domain of epidermal growth factor receptor (egfr) with a combination of three fully human monoclonal anti-egfr antibodies

Similar Documents

Publication Publication Date Title
JP2020099324A5 (enExample)
JP2017501167A5 (enExample)
JP2017514795A5 (enExample)
JP2023511595A5 (enExample)
JP2020508317A5 (enExample)
JP2017507900A5 (enExample)
RU2018146886A (ru) Пути терапевтического применения ингибитора c-raf
WO2019186273A4 (en) Subcutaneous dosing of anti-cd38 antibodies
JP2017501157A5 (enExample)
JP2018518454A5 (enExample)
JP2022512851A5 (enExample)
JP2017533912A5 (enExample)
JP2021528423A5 (enExample)
JP2011046732A5 (enExample)
JP2018505177A5 (enExample)
JP2017514461A5 (enExample)
JP2014509593A5 (enExample)
KR20200143503A (ko) 항-cd38 항체 및 레날리도마이드를 포함하는 조성물
JP2018527383A5 (enExample)
JP2014522843A5 (enExample)
JP2016519650A5 (enExample)
JP2019513726A5 (enExample)
JP2019524714A5 (enExample)
JP2022513350A5 (enExample)
JP2018529661A5 (enExample)